

#### www.mearis.cms.gov/public/home

Register: To submit and manage a MEARIS™ application or request, you must have or create a registered account.

**Login:** To log in to MEARIS™, applicants, requestors, and CMS users must be registered.

Resources: Click from a topic list to see information related to that application, request, or the MEARIS™ platform. Request application related questions can be submitted to CMS using the form available under "Contact" on the Resources screen.





# One place to manage Medicare coding and payment related applications

Register to submit applications and requests





## **Hospital Inpatient Applications and Requests**

The Inpatient Prospective Payment System (IPPS) sets forth a system of payment for operating costs of acute care hospital inpatient stays under Medicare Part A. Each case is categorized into a diagnosis-related group (DRG) and a payment weight is assigned to it. Medicare makes payments for the costs of approved graduate medical education (GME) programs to hospitals, including hospitals that are not paid under the IPPS.



Click an application to learn more about it.



New Technology Add-on Payments (NTAP)



International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS)



New & Revised Medicare Severity Diagnosis Related Groups (MS-DRG)



Requestors are strongly encouraged to review each of the links provided on the "Important Information" screen before starting a request







#### Welcome to International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) Request

nportant information	
Request Guidance	
Request Process and Timeline	
How the Online Application Works	
Preview New Code Sample Request PDF	
Click to see the latest ICD-10-PCS codes [2]	
PRA Disclosure Statement	•
	Ready to get Started?  Go  Cancel



Technical support is available under "Useful Links" at the bottom of the MEARIS™ site



## Ready to get Started?

Go

Cancel





## New ICD-10-PCS Request: Requests to add new code(s)

## **Revise ICD-10-PCS Request:**

Requests to revise existing ICD-10-PCS code(s) (e.g., add an additional approach)

### **Delete ICD-10-PCS Request:**


Requests to delete existing ICD-10-PCS code(s)

Any request submitted should include a description of the new code or change being requested, and rationale for why the new code or change is needed.





## What type of ICD-10-PCS request would you like to complete?





The Requestor Information screen is used to provide contact information for the requestor. Please note that the MEARIS<sup>TM</sup> website can only be accessed by individuals who are located in the United States.







🏫 Home 🏻 🗒 Tasks 🖹 Applications 🚢 Teams

Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS

Preview New Code Sample Request PDF [2]

Contact Info

Drug or Technology Info

New Code

NTAP Info

FDA Info

Background Paper and Attachments

Summary

#### **Requestor Information**

Please note that the MEARIS" website can only be accessed by individuals who are located in the United States.

Who is the party submitting the ICD-10-PCS request? (e.g. manufacturer, distributor, healthcare organization/entity)
Name (this is the requestor)
Name (this is the requestor) is required.

Provide contact information for the requestor.



The contact listed here will be included as a contact for this request.

First name	Middle name (optional)		Last name	
First name is required.			Last name is required.	
Organization		Occupation/Job Title		
Organization is required.		Country		
Email address		United States		
Please enter a valid email address.				
US Phone Number		Extension (optional)		
Phone Number is required.				
Mailing address line 1				
Mailing address line 1 is required.				
Mailing address line 2 (optional)				
City	State	-	Zip code	
City is required.	State is required.		Zip code is required.	
Requestor Type				

















Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS

Preview New Code Sample Request PDF [2]

Contact Info Drug or Technology Info New Code NTAP Info FDA Info Background Paper and Attachments Summary

## Who is the primary contact?

First name	Middle name (optional)		Last name	
First name is required.			Last name is required.	
Organization		Occupation/Job Title		
Organization is required.		Occupation/Job Title is required.		
US Phone Number		Extension (optional)		
Phone Number is required.		Country		
Email address		Country United States		
Please enter a valid email address.				
Mailing address line 1				
Mailing address line 1 is required.				
Mailing address line 2 (optional)				
City	State		Zip code	
No. 1 1	State is required.		Zip code is required.	
City is required.				

Back









Spartans | The International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS)

Contact Info Drug or Technology Info New Code NTAP Info FDA Info Attachments Summary

## Who is the secondary contact?

First name	Middle name (optional)		Last name	
First name is required.			Last name is required.	
Organization		Occupation/Job Title		
Organization is required.		Occupation/Job Title is required.		
US Phone Number		Extension (optional)		
Phone Number is required.		Country		
Email address		United States		
Please enter a valid email address.				
Mailing address line 1				
Mailing address line 1 is required.				
Mailing address line 2 (optional)				
City	State		Zip code	
City is required.	State is required.		Zip code is <b>required</b> .	
Relationship				

Back









Spartans | The International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS)

Contact Info

Drug or Technology Info

New Code

NTAP Info

FDA Info

Attachments

Summary

## Select the appropriate category








# Describe the drug/therapeutic agent:

- Describe the mechanism of action
  - What is it?
  - What does it do?
  - What are the procedural steps involved?
  - What are the routes of administration for the drug?

Please provide your responses in paragraph format as some of the responses on this screen will be auto-filled into the Background Paper.

# Drug/Therapeutic Agent



Back


Ne



### In paragraph form, describe:

- what condition(s) the drug/therapeutic agent is intended to treat and the population (percentage/case volume) currently affected. Explain what the current treatment/therapy is and why the new therapy is an improvement.
- the mechanism of action of the drug/therapeutic.
- If there has been any associated complications/sequela/adverse events? If yes, how many and what did they consist of? (e.g., fever, shortness of breath, anaphylaxis, etc.)

# Drug/Therapeutic Agent



Back



Back

# Drug/Therapeutic Agent


	al Classification of Diseases, 10th Revision					
tact Info	Drug or Technology Info	New Code	NTAP Info	FDA Info	Attachments	Summ
	Provide the	e utilization de	etails for thi	s drug/thera	peutic	
Identify the n	umber of times the drug/there	apeutic agent has been	(will be) administere	d.		
In clinical tria	s, this therapeutic was administer	red to 300 patients				
						1.
What is the p	ercentage of time the drug/th	erapeutic has been (wi	ll be) used across the	following care settin	gs? (optional)	69 / 3000
Hospital Inpa	ercentage of time the drug/th tient Facilities: sticipated Cases	erapeutic has been (wi	ll be) used across the	following care settin	gs? (optional)	69/3000
Hospital Inpa	tient Facilities:		ll be) used across the	following care settin	gs? (optional)	69/3000
Hospital Inpa Number of An	tient Facilities: ticipated Cases	5000	ll be) used across the	following care settin	gs? (optional)	69/3000
Hospital Inpa Number of An Percentage o	tient Facilities: hticipated Cases f Medicare beneficiaries	5000	ll be) used across the	following care settin	gs? (optional)	69/3000
Hospital Inpa Number of An Percentage of Percentage of Dutpatient Fa	tient Facilities:  ticipated Cases  f Medicare beneficiaries  f use Inpatient	5000	ll be) used across the	following care settin	gs? (optional)	69/3000
Hospital Inpa Number of An Percentage of Percentage of Outpatient Fa	tient Facilities:  aticipated Cases  f Medicare beneficiaries  f use Inpatient  acilities/Physician Office:	5000 70 % 85 %	ll be) used across the	following care settin	gs? (optional)	69/3000



# Drug/Therapeutic Agent

How is the drug/therapeutic agent documented?  How and where (e.g. O.R. Report, Notes, etc.) will the drug/therapeutic agent be documented in the medical record?  Documentation would be found in the progress notes and medication administration record (MAR)  Are there various terms that are used to describe the drug/therapeutic agent? (Please list)  Terms used to describe the drug/therapeutic are Soliris® or eculizumab		
Documentation would be found in the progress notes and medication administration record (MAR)  Are there various terms that are used to describe the drug/therapeutic agent? (Please list)	How and where (e.g. O.R. Report, Notes, etc.) will the drug/therapeutic agent be documented in the medical record?	
93 / Are there various terms that are used to describe the drug/therapeutic agent? (Please list)		
Are there various terms that are used to describe the drug/therapeutic agent? (Please list)	Documentation would be found in the progress notes and medication administration record (MAR)	
Are there various terms that are used to describe the drug/therapeutic agent? (Please list)		
Are there various terms that are used to describe the drug/therapeutic agent? (Please list)		/4
		93 / 3000
Terms used to describe the drug/therapeutic are <u>Soliris</u> ® or eculizumab	Are there various terms that are used to describe the drug/therapeutic agent? (Please list)	
	Terms used to describe the drug/therapeutic are <u>Soliris</u> ® or eculizumab	
		le
93 /		93 / 3000





Spartans | The International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS)

Contact Info Drug or Technology Info

New Code

NTAP Info

FDA Info

Attachments

Summary

## Select the appropriate category








Describe the device/technology/service or procedure.

- What is it?
- What does it do?
- How is it used?
- What are the procedural steps involved?
- If the technology is a device or implant, is only one device/implant routinely inserted or can multiple devices/implants be utilized?

Please provide your responses in paragraph format as some of the responses on this screen will be auto-filled into the Background Paper.

Back

# Procedure/Technology






# Describe the device/technology/service or procedure.

- If the technology involves a device or implant, is the device considered permanent?
- If the procedure involves
   vessels or specific body parts,
   is it beneficial or necessary to
   identify a range of the specific
   site? (E.g. 2-3 vertebrae, 4+
   vessels or stents, etc.)
- Is the procedure/technology performed in conjunction with another procedure/technology or is it considered a standalone procedure/technology?

# Procedure/Technology



Back

Next


0/3000



Provide information regarding the clinical indication for this device/technology/service or procedure.

- What diagnoses are associated with or indicated for use of the device/technology/service or procedure?
- How is the indication currently treated or managed?
- Have there been any associated complications/sequela/adverse events? If yes, how many and what did they consist of? (e.g., dislodgement, failure, loosening, etc.)

# Procedure/Technology



Back



# Procedure/Technology













Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS

Preview New Code Sample Request PDF [2]

Contact Info

Drug or Technology Info

NTAP Info

FDA Info

Background Paper and Attachments

#### Provide the Utilization details for this procedure/technology

Provide Response	
	0/300
/hat is the percentage of time the proced	ure/technology has been (will be) performed/used across the following care settings? (optional)
ospital Inpatient Facilities:	
umber of Anticipated Cases	
ercentage of Medicare beneficiaries	%
ercentage of use Inpatient	g <sub>b</sub>
utpatient Facilities/Physician Office:	
umber of Anticipated Cases	
ercentage of Medicare beneficiaries	Q <sub>f</sub> / <sub>D</sub>
ercentage of use Outpatient	a <sub>p</sub>



# Procedure/Technology











Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS Preview New Code Sample Request PDF (2) Contact Info Drug or Technology Info New Code NTAP Info FDA Info Background Paper and Attachments Summary

### How is the procedure/technology documented?

Provide Response	
e there various terms that are used to describe the procedure/technology? (Please list	0/300
e there various terms that are used to describe the procedure/technology? (Please list Provide Response	0/300

Back





Contact Info



FDA Info





Background Paper and Attachments





Summary

Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS

Preview New Code Sample Request PDF [2]

#### Select:

- **Yes** Requestor will enter the ICD-10-PCS code(s) currently used, if known, and indicate why they believe that existing codes do not adequately capture the drug or technology
- No
- Other/Don't know -Requestor will provide an explanation

Requestors will have the opportunity to provide a recommendation for possible new ICD-10-PCS code titles (e.g. approach, body part, device, qualifier)

## Are there existing codes currently being reported by facilities to describe this drug or technology?

NTAP Info


- The response to this question will be utilized to automatically populate the "Current Coding" section in your Background Paper.
- Procedure/Technology Background Paper Sample ☐ Template ☐


Drug or Technology Info


Drug/Therapeutic Agent Background Paper Sample ☐ Template ☐

Note: CMS can assist with current coding and coding options once your Background Paper is received and reviewed.

New Code









In paragraph format, indicate why existing code(s) do not adequately capture the technology/service/proced ure or the drug/therapeutic agent. Also, provide a recommendation for possible new ICD-10-PCS code titles. (e.g., approach, body part, device, qualifier).











Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS

Preview New Code Sample Request PDF [2]

Contact Info

Drug or Technology Info

New Code

NTAP Info

FDA Info

**Background Paper and Attachments** 

Summary

#### Recommended Code Titles

0	Please provide your responses in paragrap	format as some of the responses on this screen	will be auto-filled into the Background Paper
---	---	--	---

- Drug/Therapeutic Agent Background Paper Sample Template

Note: CMS can assist with current coding and coding options once your Background Paper is received and reviewed.

Provide response	
	li .
commendation for possible new ICD-10-PCS code titles. (E.g. approach, body part, device, qualifier)	0/300
Provide response	
	//
k to see the latest ICD-10-PCS codes for examples of existing code structure and convention [2]	0/200

Back



Preview New Code Sample Request PDF [2]

Contact Info

Drug or Technology Info

New Code

NTAP Info

FDA Info

Background Paper and Attachments

Summary

## Have you applied or are you applying for New Technology Add-on Payment (NTAP) for consideration?

- The response to this question will be utilized to automatically populate the "New Technology Application" section in your Background Paper.
  - Procedure/Technology Background Paper Sample 
     <u>Sample</u> 
     <u>Template</u> 
     <u>Template</u> 
     <u>Template</u> 
     <u>Sample</u> 
     <u>Sample</u> 
     <u>Template</u> 
     <u>Sample</u> 
     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 


     <u>Sample</u> 


     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u> 

     <u>Sample</u>





Click here to learn more about starting an NTAP application [4]



If the requestor has applied or is applying for New Technology Add-on Payment (NTAP), provide some details about the application.







♠ Home = Tasks = Applications = Teams





Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS

Preview New Code Sample Request PDF [2]

Contact Info

Drug or Technology Info

New Code

NTAP Info

FDA Info

Background Paper and Attachments

Summary

#### Provide some details about your NTAP application

- Please provide your responses in paragraph format as some of the responses on this screen will be auto-filled into the Background Paper.
- Drug/Therapeutic Agent Background Paper <u>Sample</u> <u>Template</u>

Name		
lew Technology Application: Provide full details regarding NTAP a	application status (intent to submit or application submission).	
Provide response		
		,
		-
		0.100
		0/30
ew Technology Application: For which Fiscal year (FY) was the/w	vill the NTAP application be submitted?	0/300
ew Technology Application: For which Fiscal year (FY) was the/w	vill the NTAP application be submitted?	0/20
	vill the NTAP application be submitted?	0/300
		0/30
ear		0/30
New Technology Application: For which Fiscal year (FY) was the/w Year  What is the NTAP application confirmation number? (optional)		0/30

Back



**Approved** – Requestor will provide the FDA approval date and specify whether the Drug/Therapeutic Agent or

Technology/Service/Procedure has received any designations, along with the date of receipt and the specific indication

Pending Approval – Requestor will provide the anticipated FDA approval date and, if applicable, any additional FDA details

Not Approved – If applicable, the requestor will provide the FDA submission date and, if applicable, any additional FDA details






Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS


Preview New Code Sample Request PDF [4]


Contact Info Drug or Technology Info New Code NTAP Info FDA Info Background Paper and Attachments Summary

## Is the drug/procedure/technology FDA approved?

- The response to this question will be utilized to automatically populate the "Food & Drug Administration (FDA) Approval" section in your Background Paper.
- Procedure/Technology Background Paper <u>Sample(3</u> <u>Template(3</u>)
- Drug/Therapeutic Agent Background Paper Sample Template









The responses entered in MEARIS™ are gathered from different sections that contain these questions to populate the background paper. Requestors must acknowledge that they have read and verified the Background Paper before submitting the ICD-10-PCS request.

CMS will be updating the draft background paper submitted and will share a revised version of the background paper with requestors for review and comment. The final background paper will be part of our Agenda and Meeting Materials packet for an ICD-10 Coordination and Maintenance Committee Meeting.





Spartans | International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) | New ICD-10-PCS 🚹 Preview New Code Sample Request PDF 🖸

Contact Info

Drug or Technology Info

NTAP Info

FDA Info

Background Paper and Attachments

#### **Background Paper Preview**



The responses below are gathered from different sections that contain these questions

- Procedure/Technology Background Paper Sample Template
- Drug/Therapeutic Agent Background Paper Sample Template

#### Issue:

There are no unique ICD-10-PCS codes to describe the administration of eculizumab (Soliris).

#### Desired Implementation Date:

April 1st

#### New Technology Application?

#### Food and Drug Administration (FDA) Approved?

Approved

#### 03/19/2007

Mar 19, 2007 Approval for Paroxysmal Nocturnal Hemoglobinuria

Sep 23, 2011 Approval for all patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Oct 23, 2017 Approval for the treatment of patients with Generalized Myasthenia Gravis (gMG)

Jun 27, 2019 Approval for the treatment of adults with Neuromyelitis Optica Spectrum Disorder

#### Background:

Soliris is used

- 1) to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria (PNH).
- 2) used to treat a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) in adults and children who weigh at least 11 pounds (5 kilograms)
- 3) used to treat myasthenia gravis in adults.
- 4) used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults.

#### Description of the Drug/Therapeutic Agent:

Soliris is a monoclonal antibody that binds to proteins in the blood that can destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells.

#### Mechanism of Action:

Eculizumab (Soliris) is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, which inhibits its cleavage into C5a and C5b and prevents the generation of the terminal complement complex C5b-9 and free C5a.

#### Inpatient Administration of the Drug/Therapeutic Agent:

Soliris is administered intravenously by a healthcare provider. The infusion can take at least 35 minutes to complete in adults, or up to 4 hours in children.

#### Adverse events associated with administration of the Drug/Therapeutic Agent:

Common Soliris side effects may include: headache, dizziness; flu symptoms (fever, tiredness, aches, cough, sore throat); runny or stuffy nose, sinus pain; painful urination; nausea, vomiting, diarrhea, stomach pain; swelling in your legs or feet; bruising; muscle or joint pain, back pain; a blood cell disorder; or high blood pressure.

#### **Current Coding:**

3E033GR Introduction of other therapeutic monoclonal antibody into peripheral vein, percutaneous approach duction of other therapeutic monoclenal antibody into central vein, percutaneous approach

☐ I acknowledge that I have read and verified the Background Paper



To be considered complete, new ICD-10-PCS procedure code request submissions through MEARIS<sup>TM</sup>

must include both a Section 508


Compliant PowerPoint and an Adobe PDF slide deck for presentation.

There should be no more than 15 slides. The content of the presentation should be focused on the need for that code and directed towards the coding professionals in attendance.

Examples of procedure code background papers and slide presentations presented at ICD-10 C&M Committee meetings can be found in agenda and meeting materials of this and previous meetings.



#### Upload Slide Deck and all supporting documentation or other reference files, if any





A downloadable PDF version of the request will be available upon successful submission. The time required for request application submission, including the time needed to gather relevant information as well as to complete the form may be extensive depending on the nature of the code request.

Requestors are encouraged to start in advance of the due date to ensure adequate time for submission.







# You have successfully submitted an International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) request



Submission Confirmation Code: ICD2410293G9QN

Confirmation details have been sent to:

a@aol.com | a@aol.com | v@aol.com |



#### So, what's next?

- An email notification has been sent to the contact(s) you provided on this request.
- . The contacts that you have identified will have access to the team and associated applications.
- . This request can be viewed under the applications list.
- · While reviewing your request, CMS may request additional information or supporting documentation.

**Back To Home**